Opendata, web and dolomites

RIPEB

Rapid heat inactivation of pathogens to enable biomarker research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RIPEB" data sheet

The following table provides information about the project.

Coordinator
DENATOR AB 

Organization address
address: DAG HAMMARSKJOLDS VAG 10A
city: UPPSALA
postcode: 751 83
website: www.denator.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.denator.com/pathogen_inactivation
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DENATOR AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The risk of epidemics due to infectious diseases caused by pathogens is an immense global challenge. The need for rapid development of vaccines, antiretroviral drugs and treatment schemes is at the top of most countries’ and organizations’ agenda. Performing biomarker research on infectious diseases is an important research area to understand and monitor disease state and progression as well as enable diagnosis and vaccine- and drug development.

The project aim is to further develop and verify the Stabilizor system to enable complete inactivation of pathogens, while still preserving sensitive biological biomarkers, in a rapid and secure manner. By preserving sensitive biomarkers early on in the analytical workflow, researchers will be able to conduct more efficient and reliable biomarker research. This will enable an accelerated process of developing vaccines and antiretroviral drugs, especially in the exploratory- and pre-clinical stages where identifying and assessing disease targets and biomarker candidates is the main focus. Also, this would allow for safe transportation of infected samples from the collection site in-field or between different laboratories to facilitate proper analysis. This will have profound social- and economic impact globally. This is of particular interest for research on highly contagious pathogens where extensive biocontainment precautions are required in enclosed laboratory facilities such as BSL-3 and -4 laboratories.

Denator’s Stabilizor system preserves the quality of biological samples from the moment of excision allowing researchers to confidently identify and verify potential biomarkers. The novelty lies in the ability to rapidly heat inactive tissue samples (within 60 seconds) to achieve both complete pathogen inactivation and ensure biomarker stability. A first customer has demonstrated complete inactivation of several infectious pathogens which is a strong proof-of-concept for the applicability of the system.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIPEB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIPEB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More